To evaluate the effect of bevacizumab on cerebral ischemia, we used 2-deoxy-2-18 F-fluoro-D-glucose ( 18 F-FDG) small-animal positron emission tomography (PET) in the middle cerebral artery occlusion (MCAO) rat model. After baseline neurologic function tests and PET studies, MCAO Sprague-Dawley rats received bevacizumab or normal saline (controls). Weekly PET imaging and neurologic function tests showed that the 18 F-FDG accumulation in the bevacizumab group was similar to that in the controls during the fi rst 2 weeks, but lower than in controls at weeks 3 and 4. However, no difference was found in neurological scores between the groups. The number of von Willebrand factor-positive cells in the bevacizumab group was lower than that in controls. The expression of vascular endothelial growth factor was higher than in controls at week 4. These results suggested that bevacizumab does not infl uence functional recovery in this model of cerebral ischemia during a 4-week period, but inhibits vascular formation and metabolic recovery, which may be considered in cancer patients with a recent ischemic stroke.
INTRODUCTION
Cerebrovascular disease (CVD) and cancer are the top two causes of morbidity and mortality in aging populations [1] [2] [3] .
Studies have shown that CVD is typically associated with ischemic stroke [4] . Ischemic stroke featuring functional disturbance and morphological damage of brain is caused by CVD, which affects the brain blood supply and leads to a cascade of metabolic alterations. Clinical presentation of CVD in cancer patients is common: 14.6% of such patients have pathologic evidence of CVD, and 7.4% show clinical symptoms [5] . Although current therapeutic strategies improve the survival rate and extend the lifetime of cancer patients, increased risk of ischemic stroke is frequently observed in the same individuals [6] . Therefore, exploring the therapeutic strategies for recent ischemic stroke in cancer patients is a serious challenge.
Currently, anti-angiogenic therapy is widely used Administration (USA) [7] for metastatic colorectal cancer [8] , 839 non-squamous non-small-cell lung cancer [8] , glioblastoma [9] , and metastatic renal cell carcinoma [10] . Many studies have demonstrated that bevacizumab therapy is associated with an increased risk of gastrointestinal perforation, wound healing complications, hemorrhage, arterial thromboembolism, and reversible posterior leukoencephalopathy syndrome [11] [12] [13] [14] . Therefore, patients with a history of bleeding, cerebrovascular accident, thrombotic disorders, and gastrointestinal perforation were excluded from participation in clinical trials [11] .
Interestingly, our recent clinical observations have shown that significantly increased numbers of elderly cancer patients treated with bevacizumab have a recent ischemic stroke. One study reported that prolonged bevacizumab treatment increases the risk of ischemic stroke [12] . However, its safety in cancer patients with recent ischemic stroke is still unknown. In the current study, we evaluated the effect of bevacizumab on recent ischemic stroke using a molecular imaging approach.
Positron emission tomography (PET) provides in vivo
metabolic information based on imaging the distribution of positron-emitting radiopharmaceuticals [15] [16] . PET can not only locate the area of infarction like MRI scanning, but also provide metabolic information, which has led to signifi cant insights into various neurologic disorders, including dementias [17] , movement disorders [18] , epilepsy [19] [20] , brain tumors [21] , neurologic infectious, and inflammatory diseases [22] [23] . Furthermore, PET imaging in neurologic disease can detect pathologic changes preceding those seen with structural imaging techniques and even clinical symptoms [24] . 2-deoxy-2-18 F-fluoro-D-glucose ( 18 F-FDG), the most extensively used PET imaging tracer, can detect subtle changes of glucose metabolism after stroke [26] . In a previous study, we successfully used 18 F-FDG small-animal PET to evaluate the metabolic recovery of the cerebral infarction in an ischemic stroke model [27] . In this study, we used 18 F-FDG PET to assess the metabolic changes, along with related immunohistochemical and functional changes, in a rat model of cerebral ischemia treated with bevacizumab.
MATERIALS AND METHODS

Animal and Experimental Design
Eight adult male Sprague-Dawley rats weighing 240-270 g 
Middle Cerebral Artery Occlusion Procedure
MCAO was induced as previously described [27] . Briefly, animals were anesthetized intraperitoneally with 1.5%
pentobarbital sodium (50 mg/kg). Body temperature was maintained at 37 ± 0.5 °C with a warm pad during the procedure. The right common, internal, and external carotid arteries were exposed. A 3-0 monofilament nylon suture with a rounded tip was inserted from the right common carotid into the internal carotid and then advanced 18-20 mm intracranially from the common carotid bifurcation in order to block the origin of the middle cerebral artery.
Approximately 90 min after MCAO, reperfusion was allowed by withdrawal of the suture. Then the muscle and skin were sutured with 4-0 nylon. Animals were given buprenorphine (0.05 mg/kg, subcutaneously) every 8 h [28] for pain palliation during the fi rst 24 h after operation.
Evaluation of Neurological Defi cits
Animals were subjected to a weekly behavioral test for 4 weeks, using the Garcia neurological grading method [29] .
This evaluation is a composite of spontaneous activity 
Statistical Analysis
Data are expressed as mean ± SEM. The independent sample-t test was used to evaluate functional recovery, the PET index, and immunohistochemically-positive cells.
Statistical analyses were performed with SPSS software (version 15.0, SPSS Inc, Armonk, NY). Values of P <0.05
were considered statistically signifi cant.
RESULTS
Infl uence of Bevacizumab on Functional Recovery
No significant difference in neurological score was detected between the groups at each time point of the 4-week experimental observation (Fig. 1) , suggesting that beva cizumab does not affect functional recovery.
Changes in Glucose Metabolism
The rats were studied using 18 F-FDG PET in order to document whether bevacizumab influences glucose metabolism. The scans allowed the visualization ( (before bevacizumab or NS injection) and at weeks 1 and 2 after MCAO. However, the percentage change in the bevacizumab-treated group was significantly lower than that in the NS group at week 3 (0.46 ± 1.15 vs 14.80 ± 2.33; P <0.05) and week 4 (6.48 ± 1.91 vs 14.64 ± 0.89; P <0.05) (Fig. 3) , indicating that bevacizumab reduces glucose metabolism in the ischemic area.
Immunohistochemistry
The results showed that the number of vWF-positive cells in the bevacizumab group was lower than that in the NS group (7.05 ± 0.43 vs 8.67 ± 0.32; P <0.01) (Fig. 4) . The IOD of VEGF in the bevacizumab group was higher than that in the NS group (15.22 ± 0.80 vs 12.83 ± 0.76; P <0.05) (Fig. 4) .
DISCUSSION
Both ischemic stroke and cancer are leading causes of morbidity and mortality among the aged worldwide. Stroke severely impacts cancer patients, while cancer increases the risk of stroke [30] . CVD occurs commonly in cancer patients, ~15% of whom experience a thromboembolic event during the clinical course [5] .
In the present study, we evaluated the effect of bevacizumab on neurogenic recovery after a recent stroke Our results demonstrated that bevacizumab had no effect on functional recovery after a recent ischemic stroke ;
however, it did suppress the recovery of cerebral glucose metabolism. Immunohistology confirmed a decrease in angiogenesis in the bevacizumab-treated group.
Our study showed no significant difference between the two groups in terms of glucose metabolic changes in the area of infarction during the fi rst 2 weeks after MCAO. receptors on the surface of endothelial cells [31] . In the current study, immunohistochemical analysis of the injured brain showed significantly lower expression of vWF but higher expression of VEGF in the treatment group than in the control group. This result indicated that bevacizumab has a strong effect on decreasing the number of vessels, consistent with a previous study [32] . However, other cancer studies [33] [34] differ from ours, in that bevacizumab was reported to reduce the high expression of VEGF. We consider that this might be due to the much lower level of VEGF expression in the ischemic brain compared to that in a tumor. In a recent study on candesartan, a drug currently used to treat hypertension, VEGF expression was found to signifi cantly increase at 2 weeks after MCAO compared to baseline [35] . Ischemic neurons increase VEGF expression by activating astrocytes, and the increase usually occurs within the first few hours of ischemic stroke [36] . Since the endpoint of our study was 28 days after bevacizumab administration, its effect on VEGF was assumed to be decreased after its biological half-life of ~5 days [37, 38] .
In conclusion, the present results indicate that attention should be paid when using bevacizumab and careful management should be provided for cancer patients 
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with recent ischemic stroke. Although the present study was done to evaluate the safety of bevacizumab in cancer patients with recent stroke using a cerebral ischemic rat model, there are several limitations in terms of sample size, dose, investigation time points, and duration of follow-up.
